scholarly journals Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor)

Cancer ◽  
2010 ◽  
pp. NA-NA ◽  
Author(s):  
Veridiana Pires de Camargo ◽  
Mary L. Keohan ◽  
David R. D'Adamo ◽  
Cristina R. Antonescu ◽  
Murray F. Brennan ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Systemic Therapy ◽  
Desmoid Tumor ◽  
Deep Fibromatosis

scholarly journals Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status

2020 ◽  
Vol 8 (2) ◽  
pp. e001007 ◽  
Author(s):  
Joao V Alessi ◽  
Biagio Ricciuti ◽  
Elizabeth Jiménez-Aguilar ◽  
Fangxin Hong ◽  
Zihan Wei ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Clinical Outcomes ◽  
Systemic Therapy ◽  
Performance Status ◽  
Small Cell ◽  
Second Line ◽  
Small Cell Lung ◽  
First Line ◽  
Ecog Ps

BackgroundPatients with non–small cell lung cancer (NSCLC) and a poor Eastern Cooperative Oncology Group Performance Status (ECOG PS) have been excluded from phase III immunotherapy clinical trials. We sought to evaluate clinical outcomes to first-line pembrolizumab in patients with advanced NSCLC, a PD-L1 Tumor Proportion Score (TPS) of ≥50%, and an ECOG PS of 2.MethodsWe performed a multicenter retrospective analysis of patients with metastatic NSCLC and a PD-L1 TPS of ≥50% (negative for genomic alterations in EGFR and ALK) who received treatment with first-line pembrolizumab. Clinical outcomes were compared in patients based on ECOG PS.ResultsAmong the 234 patients, 83.3% (n=195) had an ECOG PS of 0 or 1, and 16.7% (n=39) had an ECOG PS of 2. The baseline clinicopathological characteristics were balanced between the ECOG PS 0–1 vs 2 groups in terms of age, sex, tobacco use, histology, KRAS mutation status, presence of other potentially targetable driver mutations (BRAF, MET, HER2, RET), presence of brain metastases, and PD-L1 TPS distribution. Compared with patients with an ECOG PS of 0 or 1, patients with an ECOG PS of 2 had a significantly lower objective response rate (43.1% vs 25.6%; p=0.04), a numerically shorter median progression-free survival (6.6 months vs 4.0 months; HR 0.70 (95% CI 0.47 to 1.06); p=0.09), and a significantly shorter median overall survival (20.3 months vs 7.4 months; HR 0.42 (95% CI 0.26 to 0.68); p<0.001). On disease progression, patients with an ECOG PS of 2 were significantly less likely to receive second-line systemic therapy compared with patients with an ECOG PS of 0–1 (65% vs 22.2%, p=0.001).ConclusionsA subset of patients with NSCLC and an ECOG PS of 2 can respond to first-line pembrolizumab. However, clinical outcomes in this population are often poor and use of second-line systemic therapy is infrequent.

scholarly journals Clinical Outcomes of 42 Renal Cell Carcinoma Patients With Metastases Solely to the Lung Who Received Sorafenib as Second-line Systemic Therapy

2019 ◽  
Vol 39 (2) ◽  
pp. 1067-1072
Author(s):  
HIDEAKI MIYAKE ◽  
YUTO MATSUSHITA ◽  
HIROMITSU WATANABE ◽  
KEITA TAMURA ◽  
DAISUKE MOTOYAMA ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Clinical Outcomes ◽  
Systemic Therapy ◽  
Renal Cell ◽  
Second Line

Activity of sorafenib against desmoid tumor/deep fibromatosis (DT/DF).

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 10013-10013 ◽  
Author(s):  
M. M. Gounder ◽  
C. Antonescu ◽  
M. R. Hameed ◽  
D. R. D'Adamo ◽  
M. Keohan ◽  
...  
Keyword(s):  
Desmoid Tumor ◽  
Deep Fibromatosis

Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small-cell lung cancer and a poor performance status.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 9568-9568
Author(s):  
Joao Victor Machado Alessi ◽  
Biagio Ricciuti ◽  
Elizabeth Jimenez Aguilar ◽  
Fangxin Hong ◽  
Zihan Wei ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Clinical Outcomes ◽  
Systemic Therapy ◽  
Performance Status ◽  
Small Cell ◽  
Second Line ◽  
Small Cell Lung ◽  
First Line ◽  
Ecog Ps

9568 Background: Patients with non-small cell lung cancer (NSCLC) and a poor Eastern Cooperative Oncology Group performance status (ECOG PS) have been excluded from immunotherapy clinical trials. We sought to evaluate clinical outcomes to first-line pembrolizumab in patients with advanced NSCLC, a PD-L1 tumor proportion score (TPS) of ≥50%, and an ECOG PS of 2. Methods: We performed a multicenter retrospective analysis of patients with metastatic NSCLC and a PD-L1 tumor proportion score (TPS) of ≥50% (negative for genomic alterations in EGFR and ALK) who received treatment with first-line commercial pembrolizumab. Clinical outcomes were compared in patients based on ECOG PS. Results: Among 234 patients, 83.3% (N = 195) had an ECOG PS of 0 or 1, and 16.7% (N = 39) had an ECOG PS of 2. The baseline clinicopathological characteristics were balanced between the ECOG PS 0-1 vs 2 groups in terms of age, sex, tobacco use, histology, KRAS mutation status, presence of other potentially targetable driver mutations ( BRAF, MET, HER2, RET), history of central nervous system (CNS) disease, and PD-L1 TPS distribution. Compared to patients with an ECOG PS of 0-1, patients with an ECOG PS of 2 had a significantly lower objective response rate (ORR 43.1% vs 25.6%; P = 0.04), a numerically shorter median progression free survival (mPFS 6.6 months vs 4.0 months; P = 0.09), and a significantly shorter median overall survival (mOS 20.3 months vs 7.4 months; P < 0.001). Upon disease progression, patients with an ECOG PS of 2 were significantly less likely to receive second-line systemic therapy compared to patients with an ECOG PS of 0-1 (55.5% vs 14.3%, P < 0.001). Conclusions: Although a subset of patients with an ECOG PS of 2 can respond first-line pembrolizumab, clinical outcomes in this population are poor, and use of second-line systemic therapy is infrequent.

scholarly journals Concordant Gene Expression Signatures Predict Clinical Outcomes of Cancer Patients Undergoing Systemic Therapy

2009 ◽  
Vol 69 (21) ◽  
pp. 8302-8309 ◽  
Author(s):  
Paul D. Williams ◽  
Sooyoung Cheon ◽  
Dmytro M. Havaleshko ◽  
Hyeon Jeong ◽  
Feng Cheng ◽  
...  
Keyword(s):  
Gene Expression ◽  
Cancer Patients ◽  
Clinical Outcomes ◽  
Systemic Therapy ◽  
Gene Expression Signatures

scholarly journals A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients

2012 ◽  
Vol 23 (5) ◽  
pp. 1335-1340 ◽  
Author(s):  
A.G. Dumont ◽  
L. Rink ◽  
A.K. Godwin ◽  
M. Miettinen ◽  
H. Joensuu ◽  
...  
Keyword(s):  
Gastrointestinal Stromal Tumor ◽  
Desmoid Tumor ◽  
Case Series ◽  
Stromal Tumor ◽  
Deep Fibromatosis

scholarly journals Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy

2020 ◽  
Vol 9 (20) ◽  
pp. 7381-7387 ◽  
Author(s):  
C. Lance Cowey ◽  
Nicholas J. Robert ◽  
Janet L. Espirito ◽  
Kalatu Davies ◽  
Jennifer Frytak ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Clinical Outcomes ◽  
Squamous Cell ◽  
Systemic Therapy ◽  
Locally Advanced ◽  
Cutaneous Squamous Cell Carcinoma

scholarly journals Systemic Therapy, Clinical Outcomes, and Overall Survival in Locally Advanced or Metastatic Pulmonary Carcinoid: A Brief Report

2014 ◽  
Vol 9 (3) ◽  
pp. 414-418 ◽  
Author(s):  
Patrick M. Forde ◽  
Craig M. Hooker ◽  
Sosipatros A. Boikos ◽  
Iacope Petrini ◽  
Giuseppe Giaccone ◽  
...  
Keyword(s):  
Overall Survival ◽  
Clinical Outcomes ◽  
Systemic Therapy ◽  
Locally Advanced ◽  
Pulmonary Carcinoid
Sign in / Sign up

Export Citation Format

Share Document